Key Takeaways
- • Moderna closed a $1.5 billion five-year term loan facility with Ares Management Credit Funds, structured as non-dilutive debt across three tranches to enhance financial flexibility without equity dilution.
- • Initial funding of $600 million was drawn at closing, with two delayed draw facilities totaling $900 million available through November 2027 and November 2028, respectively, the latter contingent on regulatory milestones in Moderna's late-stage clinical pipeline.
- • The financing reinforces Moderna's path to cash breakeven by 2028, as the company maintains its 2025 financial guidance and leverages the balance sheet strength to fund its mRNA platform expansion across multiple commercial products and development programs.
- • Ares Management, a premier global alternative investment manager with deep healthcare sector expertise, structured the deal to provide flexible capital access aligned with Moderna's clinical development timelines and regulatory approval trajectory.
Summary
Moderna, Inc. (NASDAQ: MRNA) announced the closing of a $1.5 billion five-year credit facility with Ares Management Credit Funds on November 20, 2025, marking a strategic non-dilutive financing arrangement to bolster the biotechnology company's financial flexibility and balance sheet strength. The deal represents a significant capital injection for the mRNA platform leader as it advances its late-stage clinical pipeline and executes its long-term financial roadmap.
The transaction is structured across three distinct tranches with staggered availability windows. Moderna received an immediate $600 million initial term loan at closing. An additional $400 million delayed draw term loan facility (DDTL) is available for multiple draws at the company's discretion through November 2027. A third tranche of $500 million DDTL is similarly available through November 2028, contingent upon Moderna achieving key regulatory milestones aligned with its late-stage clinical development programs. This tiered structure allows Moderna to access capital on a flexible basis while maintaining alignment between funding availability and clinical progress.
Jamey Mock, Moderna's Chief Financial Officer, emphasized that the financing enhances the company's position while maintaining its strategic trajectory. "While we remain well-positioned to achieve our 2028 cash breakeven target, this additional capital enhances our strong balance sheet and enables increased flexibility over the coming years," Mock stated. The company has reiterated its 2025 financial guidance provided during third-quarter earnings disclosures, underscoring confidence in near-term operational performance.
Doug Dieter, Co-Head of Ares Specialty Healthcare, characterized the investment as timely support for Moderna's growth phase. Ares highlighted Moderna's demonstrated success with multiple commercial mRNA products and the differentiated strength of its clinical pipeline as key factors in the investment thesis. The non-dilutive structure preserves shareholder equity while providing the capital resources necessary to fund development activities, regulatory submissions, and potential product commercialization efforts across Moderna's expanding portfolio. Legal counsel from Goodwin and Proskauer supported both Moderna and Ares in structuring the transaction.
The transaction is structured across three distinct tranches with staggered availability windows. Moderna received an immediate $600 million initial term loan at closing. An additional $400 million delayed draw term loan facility (DDTL) is available for multiple draws at the company's discretion through November 2027. A third tranche of $500 million DDTL is similarly available through November 2028, contingent upon Moderna achieving key regulatory milestones aligned with its late-stage clinical development programs. This tiered structure allows Moderna to access capital on a flexible basis while maintaining alignment between funding availability and clinical progress.
Jamey Mock, Moderna's Chief Financial Officer, emphasized that the financing enhances the company's position while maintaining its strategic trajectory. "While we remain well-positioned to achieve our 2028 cash breakeven target, this additional capital enhances our strong balance sheet and enables increased flexibility over the coming years," Mock stated. The company has reiterated its 2025 financial guidance provided during third-quarter earnings disclosures, underscoring confidence in near-term operational performance.
Doug Dieter, Co-Head of Ares Specialty Healthcare, characterized the investment as timely support for Moderna's growth phase. Ares highlighted Moderna's demonstrated success with multiple commercial mRNA products and the differentiated strength of its clinical pipeline as key factors in the investment thesis. The non-dilutive structure preserves shareholder equity while providing the capital resources necessary to fund development activities, regulatory submissions, and potential product commercialization efforts across Moderna's expanding portfolio. Legal counsel from Goodwin and Proskauer supported both Moderna and Ares in structuring the transaction.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.